BIIB:NGS-Biogen Inc.

EQUITY | Drug Manufacturers | Nasdaq Global Select

Last Closing

USD 227.67

Change

0.00 (0.00)%

Market Cap

USD 69.21B

Volume

1.48M

Analyst Target

USD 261.62
Analyst Rating

Verdict

ducovest Verdict

Verdict

About

Biogen Inc is a biopharmaceutical company. It is engaged in discovering, developing, manufacturing and delivering therapies to patients for the treatment of neurodegenerative diseases, hematologic conditions and autoimmune disorders.

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2019-06-16 )

Largest Industry Peers for Drug Manufacturers

ETFs Containing BIIB

UBIO 6.30 % 0.95 %

N/A

N/A
MEDX Horizon Kinetics Medical .. 4.55 % 0.00 %

-0.05 (-0.18%)

USD 0.75B
DIP ETF Series Solutions 4.41 % 0.00 %

-0.02 (-0.18%)

USD 1.15M
BTEC:SW iShares Nasdaq US Biotech.. 3.21 % 0.00 %

-0.03 (-0.18%)

USD 0.46B
GDOC Goldman Sachs ETF Trust 2.94 % 0.00 %

-0.24 (-0.18%)

USD 0.03B
MRND 2.44 % 0.00 %

N/A

N/A
BBH VanEck Biotech ETF 0.00 % 0.35 %

-1.02 (-0.18%)

USD 0.45B
BIB ProShares Ultra Nasdaq Bi.. 0.00 % 0.95 %

-0.94 (-0.18%)

USD 0.10B
BIS ProShares UltraShort Nasd.. 0.00 % 0.95 %

+0.41 (+-0.18%)

USD 3.90M
FLAG 0.00 % 1.52 %

N/A

N/A
IBB iShares Biotechnology ETF 0.00 % 0.47 %

-1.25 (-0.18%)

USD 7.79B
MWD:CA Mackenzie Maximum Diversi.. 0.00 % 0.60 %

+0.02 (+-0.18%)

CAD 0.29B
PBE Invesco Dynamic Biotechno.. 0.00 % 0.57 %

-0.94 (-0.18%)

USD 0.24B
MXDU 0.00 % 0.34 %

N/A

N/A
DQML 0.00 % 0.00 %

N/A

N/A
JAGG 0.00 % 0.07 %

N/A

N/A
BTEC:LSE iShares Nasdaq US Biotech.. 0.00 % 0.00 %

-0.04 (-0.18%)

USD 0.49B
BTEK:LSE iShares Nasdaq US Biotech.. 0.00 % 0.00 %

-0.04 (-0.18%)

USD 0.49B
BIGT:LSE L&G Pharma Breakthrough U.. 0.00 % 0.00 %

-1.55 (-0.18%)

USD 0.02B
BIOT:LSE L&G PHARMA BREAKTHROUGH G.. 0.00 % 0.00 %

N/A

USD 8.18M
BTEE:LSE iShares Nasdaq US Biotech.. 0.00 % 0.00 %

-0.04 (-0.18%)

USD 0.49B
SCHZ Schwab U.S. Aggregate Bon.. 0.00 % 0.04 %

-0.10 (-0.18%)

USD 7.53B
VCSH Vanguard Short-Term Corpo.. 0.00 % 0.07 %

-0.06 (-0.18%)

USD 35.77B
ZBIO 0.00 % 0.95 %

N/A

N/A
LUMV:LSE Ossiam US Minimum Varianc.. 0.00 % 0.00 %

+145.00 (+-0.18%)

USD 0.01B
USMV:LSE Ossiam US Minimum Varianc.. 0.00 % 0.00 %

+2.25 (+-0.18%)

USD 0.01B
XMWD:LSE Xtrackers MSCI World Swap.. 0.00 % 0.00 %

+0.32 (+-0.18%)

USD 4.20B
XS2D:LSE Xtrackers S&P 500 2x Leve.. 0.00 % 0.00 %

+0.74 (+-0.18%)

USD 0.29B
MVUS:PA Ossiam US Minimum Varianc.. 0.00 % 0.00 %

N/A

USD 0.01B
SPMV:PA Ossiam US Minimum Varianc.. 0.00 % 0.00 %

N/A

USD 7.79M
2B70:F iShares NASDAQ US Biotech.. 0.00 % 0.00 %

-0.05 (-0.18%)

USD 0.52B
CEM2:F 0.00 % 0.00 %

N/A

N/A
OSX2:F Ossiam Lux - Ossiam US Mi.. 0.00 % 0.00 %

+0.50 (+-0.18%)

N/A
2B70:XETRA iShares Nasdaq US Biotech.. 0.00 % 0.00 %

-0.05 (-0.18%)

USD 0.52B
CEM2:XETRA 0.00 % 0.00 %

N/A

N/A
OSX2:XETRA Ossiam US Minimum Varianc.. 0.00 % 0.00 %

+1.60 (+-0.18%)

USD 0.12B
BIOT 0.00 % 0.00 %

N/A

N/A
IBBQ Invesco Nasdaq Biotechnol.. 0.00 % 0.00 %

-0.23 (-0.18%)

USD 0.03B

Market Performance

  Market Performance vs. Industry/Classification (Drug Manufacturers) Market Performance vs. Exchange (Nasdaq Global Select)
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain -24.34% 22% F 13% F
Dividend Return N/A N/A N/A N/A F
Total Return -24.34% 22% F 13% F
Trailing 12 Months  
Capital Gain -25.36% 59% D- 34% F
Dividend Return N/A N/A N/A N/A F
Total Return -25.36% 59% D- 33% F
Trailing 5 Years  
Capital Gain -26.07% 53% F 33% F
Dividend Return N/A N/A N/A N/A F
Total Return -26.07% 53% F 31% F
Average Annual (5 Year Horizon)  
Capital Gain -2.50% 44% F 29% F
Dividend Return -2.50% 42% F 26% F
Total Return N/A N/A N/A N/A F
Risk Return Profile  
Volatility (Standard Deviation) 16.82% 91% A- 71% C-
Risk Adjusted Return -14.87% 39% F 26% F
Market Capitalization 69.21B 94% A 99% N/A

Key Financial Ratios

  Ratio vs. Industry/Classification (Drug Manufacturers) Ratio vs. Market (Nasdaq Global Select)
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
Market Value  
Price / Earning Ratio 18.00 17% 43%
Price/Book Ratio 3.26 48% 32%
Price / Cash Flow Ratio 1.92 22% 46%
Price/Free Cash Flow Ratio 8.75 16% 43%
Management Effectiveness  
Return on Equity 33.36% 86% 91%
Return on Invested Capital 30.65% 99% 92%
Return on Assets 17.58% 96% 96%
Debt to Equity Ratio 44.75% 47% 49%

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Superior return on assets

The company management has delivered better return on assets in the most recent 4 quarters than its peers, placing it in the top quartile.

Superior capital utilization

The company management has delivered better return on invested capital in the most recent 4 quarters than its peers, placing it in the top quartile.

Superior return on equity

The company management has delivered better return on equity in the most recent 4 quarters than its peers, placing it in the top quartile.

Low volatility

The stock’s annual returns have been stable and consistent compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile. Although stability is good, also keep in mind it can limit returns.

High market capitalization

This is one of the largest entities in its sector and is among the top quartile. Such companies tend to be more stable.

Positive cash flow

The company had positive total cash flow in the most recent four quarters.

Positive free cash flow

The company had positive total free cash flow in the most recent four quarters.

Superior Earnings Growth

This stock has shown top quartile earnings growth in the previous 5 years compared to its sector.

High Gross Profit to Asset Ratio

This stock is in the top quartile compared to its peers on Gross Profit to Asset Ratio. This is a popular measure among value investors for showing superior returns in the long run.

What to not like:
Poor risk adjusted returns

This company is delivering below median risk adjusted returns in its peers. Even if it is outperforming on returns , the returns are unpredictable. Proceed with caution.

Highly leveraged

The company is in the bottom half compared to its sector peers on debt to equity and is highly leveraged. However, do check the news and look at its sector and management statements. Sometimes this is high because the company is trying to grow aggressively.

Overpriced on cashflow basis

The stock is trading high compared to its peers on a price to cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.

Overpriced compared to book value

The stock is trading high compared to its peers median on a price to book value basis.

Overpriced compared to earnings

The stock is trading high compared to its peers on a price to earning basis and is above the sector median.

Below median dividend returns

The company’s average income yield over the past 5 years has been low compared to its peers. However, it is not a problem if you are not looking for income.

Overpriced on free cash flow basis

The stock is trading high compared to its peers on a price to free cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.